Health Silk Road: Opportunities for Italian and Chinese pharmaceutical companies arising from the cooperation between the two countries
∎ WATCH THE VIDEO
-
Date: 29 MARCH 2021 from 10:30 to 12:00
Dr. Giorgio Foresti
Managing Director - Techdow Pharma Italy
Giorgio Foresti is graduated in Medicine and Surgery. He covered a number of roles as Director of Gruppo Menarini International Area, Sales and Marketing Director at the German pharmaceutical company, Berlin-Chemie and Business Director at Schering AG Italy.
From 2000 to 2003, Giorgio Foresti was the Vice President at Astrazeneca. From 2003 to 2006, he covered the position of Deputy General Manager at Gruppo Menarini and Chief Operations at the same group in Northern Europe branch. He was also Member of the Board at Menarini (France and Great Britain) and at Berlin-Chemie.
In 2006, Giorgio Foresti was appointed Managing Director at Ratiopharm Italy and in 2007 he received the appointment of Vice President at Assogenerici, where he covered the role of President from 2008 to 2013. Following the acquisition of Ratiopharm by the pharmaceutical industry Teva Italia, Giorgio Foresti was appointed Managing Director of Teva Italia until January 2013.
From 2013 to 2016, he was the CEO at Fidia Farmaceutici S.p.A of Albano Terme (PD). From 2016 to 2017, he was the Managing Director of AristoPharma Italy.
Since 2017, Giorgio Foresti has been working as Managing Director at the pharmaceutical company Techdow Pharma Italy. The Italian subsidiary of Techdow Pharmaceutical Co. Ltd (Shenzhen) was opened in Italy in 2017. It is a pharmaceutical company specialized in R&D, production and trade of low-molecular-weight heparin at worldwide level. The susbsidiary was launched in Italy with Inhixa, the first biosimilar of enoxaparin sodium for the Italian market.
Dr. Davide Dalle Fusine
General Manager - Chiesi Pharmaceutical Shanghai
Davide Dalle Fusine obtained a degree in Chemistry at the University of Padova and completed his studies with a post-graduate course in "Operations Management" from the Fundação Getulio Vargas, in Brazil.
From 1995 to 2003, he worked in the production area of Gruppo Chiesi: during this period, Davide Dalle Fusine spent 7 years in Brazil in order to follow the construction of a new plant and to manage the manufacturing operations in quality of Plant Manager and later as Operations Director.
In the period between 2003 and 2009, Davide Dalle Fusine covered several roles in the areas of Business Development and Business Managament in Italy, Europe, Midlle East, South America and Asia.
Before arriving in China, starting from June 2009, Davide Dalle Fusine covered the position of Director on International Commercial Operations at the headquarters of Gruppo Parma, managing the commercial partners of Chiesi in 70 countries and supporting the development of new subsidiaries in specific markets (China, Mexico, Nordics, Belgium).
Since June 2013, he is General Manager at "Chiesi Pharmaceutical Shanghai Ltd", the Chinese subsidiary of Gruppo Chiesi. Established in China in 2008, the company is involved in marketing, promotion and regulation of Chiesi portfolio within the Chinese market. Moreover, it carries on R&D activities and the management of local partnership.
Avv. Andrea Sorgato
Lawyer in Pharmaceutical and Health law in China
He deals with Healthcare since 2001, after law graduation in Catholic University of Milan. Since then, he deals with this sector – notably a multidisciplinary one – by managing issues related to relationships between healthcare industry and the National Health Service Institutions, negotiations in agreements with NHS, labour contracts of medical and nurse employees, as well as issues concerning economy drive in Healthcare industry and methods of reimbursement of health services provided by private healthcare clinics.
Since 2008 he follows pharmaceutical industry too, by assisting several pharmaceutical companies in many issues among which, for instance, market access, negotiation in reimbursement agreements between our Clients and Regulatory Authorities, generic drugs and issues concerning its originators, regulatory dossiers of drugs, biosimilars, procurement call tenders convened by NHS Institutions.
He assists Healthcare Companies in all phases related to Chinese Healthcare market access: incorporation of legal entities, scouting of suitable Chinese partner, establishment of joint-ventures, negotiation with Chinese Government Healthcare Authorities, consulting in commercial agreements with local distributors of drugs and medical devices, protection of the intellectual property.
He is Representative of public and private IRCCS Foundations for the internationalization projects of the Italian Scientific Institute for Research, Hospitalization and Healthcare.
He was assistant Professor in Administrative Law at Catholic University of Milan. He is member of the editing board “Rassegna di diritto farmaceutico e della salute” (Review of Pharmaceuticals and Healthcare Law), founded by Antonio Astolfi; he’s member of Healthcare Working Group at CICC – China-Italy Chamber of Commerce; he is consultant at the EU SME Centre for the PMI in the Healthcare sector on the Chinese market.